Compare GSK plc (GSK) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Micron Technology, Inc. — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Micron Technology, Inc. trades at $1,029 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 12.7× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Micron Technology, Inc. for 48 Days on average.
| GSK | MU | |
|---|---|---|
Market Cap | $91.88B | $1.17T |
Volume | 7,730,529 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $61.18 | $1.21K |
52-Week Low | $43.24 | $181.60 |
Typical Hold Time | 93 Days | 48 Days |
Enterprise Value | $111.88B | $1.13T |
Dividend Yield | 3.9% | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Micron Technology (MU) trades at $1,035.84, down 4.79% on the day but maintains strong technical momentum with a bullish moving average signal. The company demonstrates exceptional fundamental strength with 63.8% net income margin and 91.77% ROE, supported by three consecutive quarterly earnings beats. Recent strategic customer agreements covering 35% of revenue through 2030 provide visibility into sustained AI-driven memory demand growth.
Outlook remains positive with analyst consensus target of $1,590 representing 53% upside potential. Key opportunities include AI memory market expansion and supply constraints through 2028, while risks center on cyclical industry dynamics and potential growth deceleration. The stock's current valuation at 13.94 P/E appears reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
